Fetal cardiac arrhythmias: transplacental treatment strategies

Fetal cardiac arrhythmias demand more than a quick reading of the fetal heart rate. For Australian teams, diagnosis and management often involve obstetricians, fetal medicine specialists, sonographers, paediatric cardiologists and neonatologists working across public maternity services. This review sets out the principles of transplacental treatment strategies; it does not replace specialist assessment for an individual pregnancy. Learn more about 基礎理学療法における運動単位研究の進展.

Effective care extends beyond suppressing an abnormal rate. Clinicians must identify the arrhythmia mechanism, look for structural heart disease, assess the mother's health, and determine whether the fetus has ventricular dysfunction or hydrops fetalis. Those findings shape drug selection, surveillance, delivery timing and neonatal follow-up.

Recognising the rhythm and its causes

Fetal tachycardia is commonly defined as a sustained rate above about 160–180 beats per minute, depending on gestational age. Bradycardia below 100 beats per minute raises concern, especially if intermittent or accompanied by reduced variability. Supraventricular tachycardia (SVT) is the most frequent clinically significant tachyarrhythmia; atrial flutter, atrial fibrillation and atrioventricular (AV) block are less common but have different implications.

Causes may be idiopathic, but structural congenital heart disease, myocarditis, maternal infection, chromosomal conditions and maternal autoimmune disease all matter. Anti-Ro and anti-La antibodies can disrupt fetal conduction, particularly in pregnancies after a previous child with neonatal lupus. A normal early scan does not exclude a later arrhythmia, and hydrops fetalis can develop even when the initial rhythm assessment looks reassuring.

The FAOPS 2020 scientific programme provides historical context for the congress's emphasis on perinatal research in Tokyo. The meeting, linked with PREBIC AA 2020, was cancelled in April 2020 because of COVID-19 travel restrictions; its archived scientific material remains relevant to continuing education, although current protocols must be checked against newer guidance.

Building a reliable diagnostic pathway

Australian maternity units commonly use cardiotocography (CTG) to record fetal heart rate and uterine contractions. CTG helps identify a persistent tachy- or bradyarrhythmia and provides baseline variability, but it does not define the mechanism. A trace that looks irregular may represent a frequent premature beat, artefact or conduction block rather than SVT. Ultrasound should then assess rate, rhythm, cardiac anatomy, ventricular size and function, pericardial effusion and the presence of hydrops.

Fetal echocardiography is the key investigation when an arrhythmia persists, when there is suspected structural disease, or when treatment decisions are being made. Experienced fetal medicine specialists can distinguish SVT from atrial flutter using atrial and ventricular rates, atrioventricular valve motion and Doppler findings. Fetal ECG or magnetocardiography may help in selected centres but are not routinely available. A multidisciplinary review should document the suspected mechanism, baseline rate, variability, ventricular function and any extracardiac findings before medication is considered.

Broader motor-unit research advances offer useful background on how clinicians analyse movement signals in rehabilitation, although this work is not evidence for fetal antiarrhythmic treatment. Keeping that boundary clear helps prevent unrelated research from being applied too readily to maternal–fetal pharmacology.

Selecting transplacental treatment

Transplacental treatment relies on a maternal medicine reaching the fetus through the placenta. The drug, dose and route must account for maternal adverse effects, placental transfer, the arrhythmia mechanism and the fetus's cardiac reserve. There is no single protocol for every fetal cardiac arrhythmia, and evidence is stronger for selected uses than for others. Specialist-led protocols are essential.

For fetal SVT, flecainide and sotalol are commonly used antiarrhythmic options, with drug choice guided by local expertise and maternal factors. Digoxin may be added or substituted, especially when there is cardiac compromise, because it can improve fetal haemodynamics even when it does not promptly terminate the arrhythmia. Maternal tachycardia should be treated at the same time when present, since maternal circulation supports fetal oxygenation. Drugs with known maternal contraindications require particular caution.

Atrial flutter requires a different approach. Indirect maternal therapy is often tried, but its effect is less predictable than in fetal SVT, and rhythm conversion should not be assumed. For complete AV block, maternal corticosteroids may be considered when maternal anti-Ro/La antibodies or another inflammatory mechanism are strongly suspected. Evidence for reversing established complete block is limited, so counselling must distinguish attempts at treatment from a guaranteed cure.

Two further points prevent over-treatment. A beta-blocker prescribed for maternal arrhythmia does not necessarily correct a separate fetal re-entry tachycardia. Likewise, attempts to increase the fetal rate in bradycardia can expose the mother to tachycardia, hypotension and reduced placental perfusion. These therapies should therefore be reserved for defined specialist indications rather than used as an automatic response to an abnormal CTG.

Preventing recurrence and protecting the mother

During maternal dosing, clinicians need a written plan for drug initiation, escalation and review. Maternal observations commonly include heart rate, blood pressure, ECG where appropriate, electrolytes, renal function and drug-specific toxicity checks. Sotalol requires attention to maternal QT prolongation and heart failure; flecainide requires attention to maternal proarrhythmia and to the presence of fetal structural disease. Digoxin requires renal function and drug-interaction review. Pregnancy can alter pharmacokinetics, so a familiar adult dose is not automatically appropriate.

Fetal surveillance should match the risk and include CTG assessment, targeted ultrasound, ventricular function, growth and fluid status. The team should watch for a rising burden of arrhythmia, cardiomegaly, valvular dysfunction, pericardial effusion and evolving hydrops. Some fetuses tolerate a rhythm disturbance for weeks, while others deteriorate quickly. If there is severe dysfunction or hydrops, urgent referral for delivery at a centre with neonatal cardiology and intensive care may be safer than continued observation.

Genetic findings can alter prognosis and birth planning, so suspected chromosomal disease should trigger appropriate review rather than an assumption of idiopathic arrhythmia. The archived discussion of fetal DNA sequencing advances explains how prenatal genetic testing is developing. Cell-free DNA screening uses placental DNA and is not a direct test for fetal conduction disease; ultrasound findings or a concerning family history may still justify diagnostic karyotype, microarray or targeted testing.

Recommendations for Australian perinatal teams

Australian care pathways vary by location and funding. A patient in Melbourne may be managed through a tertiary hospital network linking fetal medicine, neonatal intensive care and paediatric cardiology, while families in Alice Springs or regional New South Wales may need telehealth, coordinated transfer and transport planning. Clear documentation of where care will occur is especially valuable when the birth setting changes.

• Confirm the rhythm mechanism and cardiac anatomy before escalating treatment, using fetal echocardiography to document ventricular function, hydrops and structural disease.
• Use a shared medication protocol covering maternal observations, fetal monitoring, escalation and stop criteria, and named specialist contacts; adapt it to pharmacy availability and local referral pathways.
• Explain the diagnosis in familiar terms—fast, slow or irregular heartbeat—alongside the medical term, so families can connect the explanation with CTG findings and the proposed birth plan.
• Check current PBS and Medicare arrangements, including whether the proposed off-label use is eligible for PBS subsidy. Public maternity services usually remove hospital charges for public patients, while private insurance and outpatient pharmacy gaps can still affect out-of-pocket costs.
• Arrange neonatal follow-up after birth, including ECG, echocardiography, medication review and advice about recurrence risk in future pregnancies.

A regional clinician can use telehealth to obtain a fetal cardiology opinion without unnecessary maternal travel, while transfer plans are developed early if the fetus develops hydrops or declining cardiac function. Family-centred communication and a documented handover help maintain continuity across shifts and institutions.

Comparing options and acting with confidence

No single medicine suits every fetal cardiac arrhythmia. The comparison below highlights the principal choices and the limitations that should shape counselling, without replacing a specialist prescription or a unit-specific protocol.

An Australian referral pathway should connect fetal medicine, obstetric cardiology, neonatology and paediatric cardiology before treatment starts, with a route for urgent transfer and postnatal review. Access to medicines, repeat echocardiography and outpatient CTG varies between public and private settings, so discharge planning should include practical checks on scripts, monitoring appointments and who will review the rhythm after birth.

Clinicians and health services can act now by sharing this review within their perinatal networks, aligning prescribing and monitoring protocols, and building referral links between regional and tertiary centres. Stronger systems mean earlier specialist review for suspected fetal cardiac arrhythmias, safer maternal–fetal treatment and a clearer plan for delivery and neonatal care.